Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home-TEA in IBS-C
NCT05519683Phase 3Recruiting
- Sponsor
- University of Michigan
- Start
- Nov 2022
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) (4 arms), sponsored by University of Michigan. Primary endpoints: Change in abdominal pain/discomfort via daily Visual Analog Scale (VAS) survey at 14 weeks and Change in global abdominal pain at 14 weeks. Started Nov 2022; status: recruiting.
02
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05519683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519683.